# A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers

> **NCT01495065** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 8 (actual)

## Conditions studied

- Community-acquired Infection

## Interventions

- **DRUG:** GSK2251052 750 mg
- **DRUG:** GSK2251052 1500 mg
- **DRUG:** GSK2251052 1500 mg BID
- **DRUG:** GSK2251052 2250 mg
- **DRUG:** GSK2251052 3000 mg
- **DRUG:** GSK2251052 0.9% saline

## Key facts

- **NCT ID:** NCT01495065
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12-19
- **Primary completion:** 2012-02-17
- **Final completion:** 2012-02-17
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01495065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01495065, "A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01495065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*